FSD Pharma (TSE:HUGE) has released an update.
FSD Pharma Inc. has announced IRB approval to proceed with their METAL-2 trial in the United States, focusing on the safety and efficacy of their product Unbuzzd™ for acute alcohol intoxication. This development is a significant step for the biopharmaceutical company, which specializes in addressing various ailments including neurodegenerative and metabolic disorders. FSD Pharma, also invested in Lucid Psycheceuticals, retains ownership in Celly Nutrition Corp. and stands to benefit from future royalties and tax offsets.
For further insights into TSE:HUGE stock, check out TipRanks’ Stock Analysis page.
